These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 19031743)

  • 41. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
    Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
    Jagannath S; Durie BG; Wolf JL; Camacho ES; Irwin D; Lutzky J; McKinley M; Potts P; Gabayan AE; Mazumder A; Crowley J; Vescio R
    Br J Haematol; 2009 Sep; 146(6):619-26. PubMed ID: 19622094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
    Guo H; Zhou X; Jiang Y; Yang G; Sun C; Zhuang Y; Sun H; Lu M; Qian X; Chen F; Mao J; Chen H; Xia J; Shen Y
    Am J Hematol; 2010 Jul; 85(7):499-501. PubMed ID: 20575036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff MH; Bisping G; Wenning D; Volpert S; Tchinda J; Berdel WE; Kienast J
    Leuk Res; 2005 May; 29(5):587-90. PubMed ID: 15755512
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
    Lonial S; Cavenagh J
    Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
    Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
    Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
    Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
    Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
    Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
    Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
    J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
    Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
    Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1115-21. PubMed ID: 20197100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L; Iacobelli S; Moreau P; Dib M; Lafon I; Niederwieser D; Masszi T; Fontan J; Michallet M; Gratwohl A; Milone G; Doyen C; Pegourie B; Hajek R; Casassus P; Kolb B; Chaleteix C; Hertenstein B; Onida F; Ludwig H; Ketterer N; Koenecke C; van Os M; Mohty M; Cakana A; Gorin NC; de Witte T; Harousseau JL; Morris C; Gahrton G
    J Clin Oncol; 2012 Jul; 30(20):2475-82. PubMed ID: 22585692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.
    Chen SL; Jiang B; Qiu LG; Yu L; Zhong YP; Gao W
    Anat Rec (Hoboken); 2010 Oct; 293(10):1679-84. PubMed ID: 20734318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
    Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Algarotti A; Pascutto C; Lazzarino M
    Eur J Haematol; 2009 Nov; 83(5):449-54. PubMed ID: 19519727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.